Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2494 PWToday Stories

ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen

20 Dec 16

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that both of its Phase  III studies to evaluate the safety and efficacy of switching virologically suppressed patients from a three or four-drug (integrase inhibitor-, non-nucleoside reverse transcriptase inhibitor-, or boosted protease inhibitor-based) antiretroviral regimen to a two-drug regimen of dolutegravir (ViiV Healthcare) and rilpivirine (Janssen Sciences Ireland UC) met the primary endpoint of non inferiority at Week 48.

The primary endpoint, based on FDA’s snapshot analysis, was evaluated as the proportion of patients with plasma HIV-1 RNA <50 copies per milliliter (c/mL) at Week 48.

The safety profiles for dolutegravir and rilpivirine in these studies were consistent with the product labelling for each medicine.  Detailed results from the studies will be presented at an upcoming scientific meeting.


Dominique Limet, CEO ViiV Healthcare, said “These are important results for the HIV scientific community and represent an important milestone in our understanding of how HIV can be treated.  The results support our strategy of investigating two-drug regimens as innovative treatment options for people living with HIV and we are planning regulatory submissions for this two-drug regimen as a single tablet in 2017.”

The use of dolutegravir and rilpivirine as HIV maintenance treatment is investigational and not approved anywhere in the world.

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.